A detection kit for non-small cell lung cancer and its application

Abstract

The invention belongs to the field of tumor biomarkers and tumor diagnosis, and in particular relates to a non-small cell lung cancer detection kit and application thereof. The present invention finds for the first time that FGF19 and β-klotho can be used individually or in combination as biomarkers for early diagnosis, selection of treatment options, and prognosis assessment of non-small cell lung cancer, with high specificity and good sensitivity. It can realize the early in vitro diagnosis of non-small cell lung cancer, overcome the limitation that most of the original non-small cell lung cancer detection is biopsy detection, and overcome the shortcomings of the existing non-small cell lung cancer serum detection that is cumbersome and has many false positives.

Description

technical field [0001] The invention belongs to the field of tumor biomarkers and tumor diagnosis, and in particular relates to a non-small cell lung cancer detection kit and application thereof. Background technique [0002] Lung cancer can be divided into multiple tissue types according to different pathological characteristics. Different types of lung cancer have different treatment measures and prognosis effects. The histopathological classification of common lung cancer is divided into non-small cell carcinoma (NSCLC) and small cell carcinoma (SCLC). Non-small cell carcinoma is divided into squamous cell carcinoma (SCC), adenocarcinoma (AC) and large cell carcinoma (LCC), among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80-85% of primary lung cancer . Once discovered, non-small cell lung cancer is generally in the middle and late stage, and the surgical treatment effect is not good. Therefore, the early diagnosis of non-sm...

AI Technical Summary

Problems solved by technology

However, its use is limited due to high false alarm rate, potential overdiagnosis, high cost, and possible radiation exposure hazards.

And tissue biopsy, such as based on lung cancer markers, such as SALL4 (patent number CN105044348A), EIF4G1 (CN105624275A) and other detections, has positive significance for the treatment of lung cancer, but it is traumatic to patients and cannot be used for early diagnosis of lung cancer.

Most of the emerging in vitro detection of lung cancer is based on the content of lung cancer markers micRNA in serum, such as miR-106a, miR-20a, (CN106350582A) miR 3613 (CN105603117A), etc., to achieve early diagnosis of lung cancer and screening of high-risk groups, but the use of nucleic acid The detection mechanism of the detection is relatively complex, the sample requirements are high and false positives are prone to occur

In summary, the current lung cancer detection methods have major defects, and there is no effective clinical method for early diagnosis of lung cancer and screening of high-risk groups

Images